Table 1 Patient demographics and clinical characteristics at baseline (treated set)
| Â | Total study population |
|---|---|
Patients (n) | 42 |
Age (years) | 60.3 (6.0) |
Male (%) | 66.7 |
Race (%) | |
 White | 97.6 |
 Asian | 2.4 |
Height (cm) | 170.1 (8.6) |
Body weight (kg) | 87.7 (12.2) |
Body mass index (kg/m2) | 30.3 (3.0) |
Hypertension (%) | 54.8 |
Smoking status (%) | |
 Never smoked | 57.1 |
 Ex-smoker | 42.9 |
Alcohol status (%) | |
 Non-drinker | 21.4 |
Concomitant medication (%) | |
 Statins | 21.4 |
 ACE inhibitors | 28.6 |
 Aspirin | 7.1 |
 β-Blockers | 7.1 |
|  | Linagliptin 5 mg | Glimepiride 1–4 mg | Placebo |
|---|---|---|---|
Patients (n) | 40 | 41 | 40 |
HbA1c* (%) | 7.41 (0.61) | 7.41 (0.61) | 7.41 (0.61) |
FPG (mg/dL) | 135.8 (3.7) | 134.5 (3.1) | 137.1 (4.2) |
Lipids | |||
 LDL cholesterol†(mmol/L) | 2.80 (0.83) | 2.92 (0.80) | 2.80 (0.84) |
 HDL cholesterol†(mmol/L) | 1.20 (0.38) | 1.20 (0.36) | 1.20 (0.36) |
 Total cholesterol†(mg/dL) | 188.1 (17.1) | 190.9 (16.3) | 189.5 (16.4) |
 Triglycerides†(mg/dL) | 151.2 (46.9) | 153.6 (45.7) | 169.9 (134.8) |
Brachial artery diameter (FMD)c (mm) | |||
 Fasting, day −1 | 4.51 (0.56) | 4.62 (0.60) | 4.60 (0.58) |
 day 28 | 4.50 (0.50) | 4.52 (0.50) | 4.53 (0.51) |
 2-h postprandial, day −1 | 4.54 (0.52) | 4.57 (0.61) | 4.60 (0.64) |
 day 28 | 4.49 (0.56) | 4.59 (0.60) | 4.51 (0.56) |
Brachial artery diameter (NMD)‡ (mm) | |||
 2-h postprandial, day −1 | 4.54 (0.55) | 4.58 (0.63) | 4.62 (0.60) |
 day 28 | 4.52 (0.56) | 4.60 (0.58) | 4.57 (0.48) |
SBP§ (mmHg) | 138.8 (12.9) | 139.3 (12.7) | 138.8 (12.9) |
DBP§ (mmHg) | 84.2 (6.9) | 84.2 (7.0) | 84.2 (6.9) |
Heart rate§ (bpm) | 68.4 (9.5) | 67.7 (9.8) | 68.4 (9.5) |